Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Recommendation of “Moderate Buy” from Analysts

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $11.00.

Several research firms recently weighed in on EVAX. Maxim Group began coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price target on the stock. JonesTrading began coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a research report on Friday, April 24th. Wall Street Zen lowered shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Lake Street Capital lowered their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, March 9th.

Evaxion A/S Stock Up 0.8%

Shares of NASDAQ EVAX opened at $3.64 on Friday. The stock has a market capitalization of $30.36 million, a P/E ratio of -2.48 and a beta of 0.24. The company has a 50-day moving average price of $4.05 and a 200-day moving average price of $4.23. Evaxion A/S has a 1 year low of $2.07 and a 1 year high of $12.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85.

Evaxion A/S (NASDAQ:EVAX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, equities research analysts forecast that Evaxion A/S will post -0.5 EPS for the current fiscal year.

Institutional Trading of Evaxion A/S

Several hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S in the fourth quarter worth about $38,000. Wesbanco Bank Inc. bought a new stake in Evaxion A/S in the fourth quarter worth about $48,000. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S in the fourth quarter worth about $72,000. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Evaxion A/S in the first quarter worth about $112,000. Finally, Renaissance Technologies LLC bought a new stake in Evaxion A/S in the first quarter worth about $146,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.